Volume 26, Number 10—October 2020
Research
Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland
Table 3
Reported and measured detection and testing rates of toxigenic Clostridioides difficile, Switzerland, 2015*
Institutions and testing methods | Reported rate/10,000 patient bed-days | Measured rate/10,000 patient bed-days, winter (range) | Measured rate/10,000 patient bed-days, summer (range) | Mean measured rate/10,000 patient bed-days (range) | Testing rate/10,000 patient bed-days (range) |
---|---|---|---|---|---|
All institutions | 3.8 (0–11) | 67.5 (0–3,202) | |||
EIA | 6.4 (0–387) | 5.7 (0–475) | 6.1 (0–475) | ||
NAAT |
11.4 (0–387) |
7.1 (0–475) |
9.3 (0–475) |
||
Children’s hospitals | 1.1 (0.4–1.1) | 22.5 (7.0–46.7) | |||
EIA | 33.7 (0–73) | 0 | 16.9 (0–73) | ||
NAAT | 67.3 (0–99) | 0 | 33.6 (0–99) |
EIA, enzyme immuno assay; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification tests.